Hong Kong · Delayed Price · Currency is HKD VISEN Pharmaceuticals Company Description
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland.
The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency.
It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism, which has completed phase 3 clinical trial.
It has strategic collaboration agreements with Shanghai Pharmaceutical, XtalPi, Anke Bio, and the United Family Healthcare.
VISEN Pharmaceuticals was incorporated in 2018 and is headquartered in Suzhou, China.
| Country | Cayman Islands |
| Founded | 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 82 |
| CEO | An-bang Lu |
Contact Details
Address: Building B, Hengtai Lixiang Chuangxin Tower Suzhou China | |
| Website | visenpharma.com |
Stock Details
| Ticker Symbol | 2561 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG93Y5D1039 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| An-bang Lu | Chief Executive Officer and Executive Director |
| Ying Lu | Chief Financial Officer |
| Dr. Jun Chen Ph.D. | Chief Commercial Officer |
| Sze Ting Chan A.C.S. | Company Secretary |